logo
We Like A10 Networks' (NYSE:ATEN) Earnings For More Than Just Statutory Profit

We Like A10 Networks' (NYSE:ATEN) Earnings For More Than Just Statutory Profit

Yahoo14-05-2025

A10 Networks, Inc.'s (NYSE:ATEN) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. Our analysis suggests that shareholders might be missing some positive underlying factors in the earnings report.
We check all companies for important risks. See what we found for A10 Networks in our free report.
As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.
Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.
For the year to March 2025, A10 Networks had an accrual ratio of -0.25. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free cash flow of US$61m during the period, dwarfing its reported profit of US$50.0m. A10 Networks did see its free cash flow drop year on year, which is less than ideal, like a Simpson's episode without Groundskeeper Willie. However, that's not all there is to consider. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio.
See our latest analysis for A10 Networks
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Surprisingly, given A10 Networks' accrual ratio implied strong cash conversion, its paper profit was actually boosted by US$5.7m in unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).
In conclusion, A10 Networks' accrual ratio suggests its statutory earnings are of good quality, but on the other hand the profits were boosted by unusual items. Based on these factors, we think that A10 Networks' profits are a reasonably conservative guide to its underlying profitability. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. At Simply Wall St, we have analyst estimates which you can view by clicking here.
In this article we've looked at a number of factors that can impair the utility of profit numbers, as a guide to a business. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

1981 Honda Accord SE Pushes Honda into $10K Territory
1981 Honda Accord SE Pushes Honda into $10K Territory

Car and Driver

time30 minutes ago

  • Car and Driver

1981 Honda Accord SE Pushes Honda into $10K Territory

From the March 1981 issue of Car and Driver. The rep for the American Honda Motor Company, Inc., when he handed over the keys to the fresh-off-the-boat 1981 Accord SE, lowered his voice to a conspiratorial tone and said, "This is just a little testing of the waters—to see if Honda can sell in the BMW price range." "SE," in case you haven't heard, stands for "Special Edition," and those words will ap­pear in delicate chrome script on the Glacier Grey Metallic flanks of a mere 3000 Accord four-doors this year. These specially anoint­ed sedans will carry every option in the Hon­da book, including power windows, power steering, power brakes, Michelin radials, four-speaker AM/FM/cassette stereo, and air conditioning. Beyond that extends a long list of fitments that are not in the Honda book­—at least they weren't until now—including power antenna, folding rear-seat armrest, al­loy wheels, special gray deep-pile carpeting, and genuine Connolly leather on the seats. This, you might conclude, is intended to be one plush little unit. View Photos Patrick Bedard | Car and Driver Hearing all of this, and knowing how crazy car prices have become in recent months, we ventured a tentative "How much?" "Only $9950," was the answer. Aargh! A $10,000 Honda! "That's the five-speed. The automatic is 10,200," he said. How can a Honda cost $10,000? You guys keep it simple, right? You're the company that removed the stigma from small-car own­ership. It was okay to have a Honda. Rich people bought them. But this Special Edition is a cop-out. Any company can be in the stig­ma-free-small-car business if it charges a lot of money. "Yeah, but the SE has all the stuff. You take your base Accord at $7435, add $600 for air, $500 for the digital cassette radio. Al­ready it's $8500. This is a great deal." View Photos Patrick Bedard | Car and Driver Well, folks, maybe it is. But looking at the parts list, we come away with the idea that a few bits of trim add 1500 bucks to the price. Of a Honda. It wasn't so long ago that you could get a whole Honda for that money. For the full several hundred miles of our evaluation drive, this five-digit price kept nagging at the old editorial sense of value. This is a $10,000 Honda? And if it is, then what must rutabagas be going for down at the Hy-Vee? Certainly the Special Edition gives every indication of being a Honda. It has all those little idiosyncrasies we've grown accustomed to: the soft chattering when you engage the clutch and the gentle bucking of the engine when you ask it to accelerate from low revs. View Photos Patrick Bedard | Car and Driver But the old Honda charm is there, too. The engine climbs happily to the redline. The body doesn't creak and groan. The inte­rior is perfectly assembled—nary a loose thread or smear of adhesive to catch the crit­ical eye. And the luxury touches are so tastefully and confidently done. The trunk is thickly carpeted and fitted with small bins on the sides to hold minor objects that you don't want to roll around. The interior is a light dove gray, very popular at Ford a few years back but still fashionable enough. And the seats really are leather, exuding just a trace of the aroma that Connolly also imparts to every Rolls-Royce and Jaguar. Moreover, the Special Edition seems to work better than any Accord we've ever driv­en. The usually flaccid shock absorbers seem a bit tauter. The shape of the seat is correct, its depression for your butt back where it be­longs now, rather than halfway forward in typical Japanese fashion. The power steering isn't as numb as it used to be. The direction­al stability is better. The car more graceful. Its mood more, well, BMW-like. Of course, we car critics can still find faults. The power-window controls are big and bulky, looking very much like the tack­-ons they are. The stereo sounds as though it has K-mart speakers. And the radio itself has so many tiny buttons, with such small de­scriptions of what they do, that you practical­ly have to pull over to the side of the road just to change from AM to FM. But it'll sure do some tricks, this radio, and the car around it is such a jewel that maybe $10,000 really is fair. Certainly there's noth­ing else on the market with similar quality, luxury, and efficiency for ten grand. View Photos Patrick Bedard | Car and Driver Just when we had convinced ourselves that there is value in a $10,000 Honda, we saw a dealer ad in the classified section of the New York Times brazenly offering an SE five-speed for $13,950. Apparently while the American Honda Motor Company is merely testing the BMW waters, dealers are jumping right in. They may be avaricious and unconsciona­ble opportunists, the car dealers of this coun­try, but one thing you have to give them: they do know what cars are worth. Specifications Specifications 1981 Honda Accord Vehicle Type: front-engine, front-wheel-drive, 4-passenger, 4-door sedan PRICE Base/As-Tested: $9950/$9950 ENGINE SOHC inline-4, iron block and aluminum head Displacement: 107 in3, 1750 cm3 Power: 75 hp @ 4500 rpm TRANSMISSION 5-speed manual DIMENSIONS Wheelbase: 93.7 in Length: 171.9 in Curb Weight (C/D est): 2250 lb EPA FUEL ECONOMY City: 27 mpg

VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm
VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm

Business Wire

time32 minutes ago

  • Business Wire

VSTS Investors Have Opportunity to Lead Vestis Corporation Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vestis Corporation ('Vestis' or 'the Company') (NYSE: VSTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 2, 2024 and May 6, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 8, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Vestis misled investors about the actual extent of its ability to grow the business. The Company was not equipped to execute on planned strategic initiatives. The Company struggled to bring in new customers and retain existing customers. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Vestis, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

2 Weight Loss Drug Stocks That Are Screaming Buys in June
2 Weight Loss Drug Stocks That Are Screaming Buys in June

Yahoo

time35 minutes ago

  • Yahoo

2 Weight Loss Drug Stocks That Are Screaming Buys in June

Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store